Compare · ICCM vs RMD
ICCM vs RMD
Side-by-side comparison of IceCure Medical Ltd. (ICCM) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICCM and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.02B, about 2742.3x ICCM ($10.2M).
- Over the past year, ICCM is down 87.9% and RMD is down 23.1% - RMD leads by 64.8 points.
- Both names hit the wire about 6 times in the past 4 weeks.
- RMD has more recent analyst coverage (25 ratings vs 2 for ICCM).
- Company
- IceCure Medical Ltd.
- ResMed Inc.
- Price
- $3.69-15.17%
- $193.21-1.43%
- Market cap
- $10.2M
- $28.02B
- 1M return
- -50.92%
- -6.57%
- 1Y return
- -87.88%
- -23.07%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 6
- Recent ratings
- 2
- 25
IceCure Medical Ltd.
IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for women's health and oncology markets. It offers ProSense system, a cryoablation solution for breast tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest ICCM
- SEC Form 6-K filed by IceCure Medical Ltd.
- IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance
- SEC Form 6-K filed by IceCure Medical Ltd.
- SEC Form 4 filed by VP, R&D & Engineering Muchnik Naum
- New insider Peleg Meir claimed ownership of 400,000 units of Ordinary shares (SEC Form 3)
- SEC Form 4 filed by Chief Financial Officer Tsimerman Ronen
- SEC Form 6-K filed by IceCure Medical Ltd.
- IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
- SEC Form 424B5 filed by IceCure Medical Ltd.
- SEC Form 6-K filed by IceCure Medical Ltd.
Latest RMD
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett
- SEC Form 8-K filed by ResMed Inc.